March 14, 2014
Pfizer is cutting off all clinical trials and development for a cholesterol drug that was expected to be the company's star product.
The decision was based on an unexpected number of deaths and cardiovascular problems in patients who'd used the medicine.
Pfizer says it was told that an independent board monitoring a study for the drug Torcetrapib had recommended that the work end.
The drug is supposed to raise levels of good cholesterol.